Dificid (Fidaxomicin) Patent Expiration, LOE Window & CMS Spending

Dificid (Fidaxomicin) by Merck & Co.: FDA Orange Book core substance LOE 2028-01-31, 5 AB generics, $176.5M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerck & Co.
FDA Application & PathwayN201699 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2028-01-31
Last Listed Patent or Exclusivity Date2028-01-31
Orange Book Patents (*PED Extensions)8 patents (4 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$176.5M
2024 Medicare Part D Spend$153.8M
2024 Medicaid Spend$22.7M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 16.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.